Type 1 Diabetes Clinical Trial Aims to Retrain Immune System

Type 1 diabetes (T1D) is a chronic condition in which your immune system mistakenly attacks healthy insulin-producing cells in the pancreas and destroys them. This results in the pancreas making little or no insulin. Insulin allows blood sugar to enter cells around your body to be used for energy, but a lack of it can cause your blood sugar to rise to dangerous levels. 

While a cure for T1D remains undiscovered, researchers at Benaroya Research Institute at Virginia Mason (BRI) are working on innovative therapies to treat this disease. BRI is now starting the TOPPLE Study, a clinical trial to test a new potential therapy designed to teach the immune system to stop attacking cells in the pancreas.

TOPPLE is a Phase 1 trial, which means this therapy is being tested in people to assess its safety, look for side effects and determine the appropriate dosage. As of now, this study is actively recruiting participants to help researchers uncover more information and move them closer to better treatment options for this debilitating disease.

Eligible participants include those between the ages of 18-45 who have been diagnosed with type 1 diabetes in the last four years.

You can learn more about the TOPPLE Study on BRI’s website here. If you’re interested in getting involved with this study, please contact BRI at 800-888-4187 or Diabetes@BenaroyaResearch.org.

Leave a Reply

%d bloggers like this: